TX-OURO
Ouro, a global financial services and technology innovator, and the Real Madrid Football Club today announced a strategic partnership agreement to develop and deliver co-branded financial solutions to fans in key markets globally, including the United States, Mexico, Brazil, Portugal, France and the United Arab Emirates. The alliance makes Ouro the exclusive partner of the men's and women's football teams for the prepaid, debit and credit card product categories.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424106690/en/
The signing event held April 15 in Madrid with Ouro founders Bertrand Sosa and Roy Sosa and Emilio Butragueño, Real Madrid’s Director of Institutional Relations. (Photo: Business Wire)
From the April 15 signing event in Madrid, Emilio Butragueño, Real Madrid’s Director of Institutional Relations, commented, “It’s hugely gratifying. They are leaders in financial services who will partner with us in countries around the world. We share a commitment to values like constant reinvention and trying to get better everyday that are as fundamental to our organizations as integrity. We look forward to an enduring and rewarding partnership.”
As an official partner to Real Madrid in these countries, Ouro will unite the Real Madrid brand and Madridista loyalty program benefits with Ouro branded products and their unique functionalities – this includes Ouro’s flagship Netspend brand which pioneered prepaid debit for underserved consumers across the U.S., and its more recently developed X World Wallet that offers a multi-currency wallet and payments app for mobile, multicultural consumers.
“We are honored to join forces with such a storied and beloved global brand to make financial empowerment products more accessible to more people,” said Bertrand Sosa, president and chief brand officer, Ouro. “This unique opportunity to help people take their money further so they can experience more of what they love is the motivation behind our work, and to have Real Madrid collaborate with us to deliver even more value to such a passionate fan base is very special.”
By joining sports loyalty with financial solutions, Ouro and Real Madrid aim to deepen the Madridistas’ connection with their club, maximize the value of their money and promote financial responsibility and accessibility. The partnership also supports Ouro’s strategic focus on innovation, growth, and expansion to global markets.
“We are proud to announce our partnership with Real Madrid, a global icon that shares our values of excellence, winning spirit, solidarity, and humility,” added Roy Sosa, Ouro CEO and Co-founder. “Today we start a movement that transcends sports. Together, we will empower millions of fans and customers to achieve their financial goals and turn their dreams into reality.”
The partnership will soon launch a co-branded Netspend card featuring the Real Madrid brand in the U.S. in anticipation of the team’s upcoming U.S. Summer Tour.
The partners have also started joint development of a co-branded financial product combining the loyalty benefits of the Madridista Club membership with a digital multi-currency wallet they will begin rolling out to fans around the world later this year. Loyal Real Madrid fans can expect these payment products to bring them even closer to the action, with special access to discounts and experiences at the point of sale and beyond.
Fans who want to be among the first to know about availability where they live can now join the waitlist at ouro.com/realmadrid.
About Ouro
Ouro is a global, vertically-integrated financial services and technology company dedicated to the delivery of innovative financial empowerment solutions to consumers worldwide. Ouro's financial products and services span prepaid, debit, cross-border payments, and loyalty solutions for consumers and enterprise partners. Since its founding in 1999 by industry pioneers Roy and Bertrand Sosa, Ouro products have processed almost a trillion dollars in transaction volume and served millions of customers worldwide. The company is headquartered in Austin, Texas with regional offices across the world. For more information, visit ouro.com.
About Real Madrid
Real Madrid C.F. is a sport entity with 122 years of history. It is the club with the most European Cups of both football (14) and basketball (11) and was awarded by FIFA as the Best Club of the twentieth century. Real Madrid has millions of fans in all corners of the world, with more than 534 million followers on social media, being the strongest football brand in the world according to Brand Finance for the second year in a row and also the highest earning football club in the world in the 22-23 season (Football Money League by Deloitte). More information about Real Madrid C.F. is available at www.realmadrid.com, the most visited football club website for the seventh consecutive year.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240424106690/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom